So far Edge Trial Assurance has been used in 30 trials. It has detected 50-75 data anomalies in every single trial.
According to a 2016 industry survey, 80% of respondents agreed that Phase I studies are becoming more complex.
Discoveries driven by genomic data could dramatically increase the number of biomarkers available for use in clinical trials.
The Key is Historical Study Data (Lots of It) and Artificial Intelligence